2026-03-09T09:05:50Z https://tokushima-u.repo.nii.ac.jp/oai

oai:tokushima-u.repo.nii.ac.jp:02010117 2025-05-29T04:13:07Z 1713853213384:1713853295607

Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion 軒原, 浩 ノキハラ, ヒロシ Nokihara, Hiroshi 荻野, 広和 オギノ, ヒロカズ Ogino, Hirokazu 荻野 オギノ Ogino 広和 ヒロカズ Hirokazu 00833732 三橋, 惇志 ミツハシ, アツシ Mitsuhashi, Atsushi 三橋 ミツハシ Mitsuhashi 惇志 アツシ Atsushi コンドウ, ケンスケ コンドウ, ケンスケ Kondo, Kensuke オガワ, エイ オガワ, エイ Ogawa, Ei 尾崎, 領彦 オザキ, リョウヒコ Ozaki, Ryohiko 尾崎 オザキ Ozaki 領彦 リョウヒコ Ryohiko 矢葺, 洋平 ヤブキ, ヨウヘイ Yabuki, Yohei 矢葺 ヤブキ Yabuki 洋平 ヨウヘイ Yohei 米田, 浩人 ヨネダ, ヒロト Yoneda, Hiroto 大塚, 憲司 オオツカ, ケンジ Otsuka, Kenji 西岡, 安彦 ニシオカ, ヤスヒコ Nishioka, Yasuhiko 西岡 ニシオカ Nishioka 安彦 ヤスヒコ Yasuhiko open access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Non-small cell lung cancer Epidermal growth factor receptor Osimertinib Pleural effusion Background: Osimertinib is a standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Although malignant pleural effusion (PE) is a common clinical problem in NSCLC, information about the efficacy of osimertinib in patients with PE is limited, especially regarding its efficacy in EGFR T790M-negative patients with PE remains unclear. Methods: We retrospectively reviewed the medical records of patients with NSCLC harboring EGFR mutations who were treated with osimertinib in our institution between May 2016 and December 2020. Results: A total of 63 patients with EGFR mutated NSCLC were treated with osimertinib; 33 (12 with PE) had no EGFR T790M mutation, while 30 (12 with PE) had EGFR T790M mutation. In EGFR T790M-negative NSCLC, the progression-free survival (PFS) of the patients with PE was comparable to that of the patients without PE (median PFS 19.8 vs. 19.8 months, p = 0.693). In EGFR T790M- positive NSCLC, the PFS and overall survival (OS) of the patients with PE were significantly shorter than those of the patients without PE (median PFS 16.8 vs. 8.3 months, p = 0.003; median OS 44.9 vs. 14.2 months, p = 0.007). In the multivariate analysis, the presence of PE was independently associated with shorter PFS and OS in EGFR T790M-positive NSCLC patients, but not EGFR T790M-negative patients. Conclusions: These data suggest the efficacy of osimertinib may differ between EGFR T790M-positive and -negative NSCLC patients with PE. BioMed Central Springer Nature 2022-06-01 eng journal article VoR 387314 https://tokushima-u.repo.nii.ac.jp/records/2010117 https://doi.org/10.1186/s12885-022-09701-2 10.1186/s12885-022-09701-2 14712407 AA12034763 BMC Cancer 22 597 https://tokushima-u.repo.nii.ac.jp/record/2010117/files/BMCCan_22_597.pdf application/pdf 1.05 MB 2022-08-04